Method for producing cell-free plasma or serum
Ultrasonic disruption treatment of plasma or serum with controlled power and subsequent cell removal addresses the challenges of filter clogging and growth factor concentration in existing methods, achieving efficient production of cell-free plasma or serum enriched with VEGF or IGF1.
Patent Information
- Application Number
- PCT/JP2024/018431
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-20
- Publication Date
- 2024-12-05
AI Technical Summary
Current methods for producing cell-free plasma or serum enriched with VEGF or IGF1 face challenges such as clogging during filtration, reduced concentration of growth factors, and the need for filter replacement, especially after centrifugation, which complicates plasma processing and reduces the efficiency of growth factor concentration.
The method involves ultrasonic disruption treatment of plasma or serum with an output of 5W to 500W, followed by removing cells to produce cell-free plasma or serum enriched with VEGF or IGF1, using techniques like centrifugation and filtration with specific filter pore sizes to maintain operability and prevent clogging.
This approach effectively concentrates VEGF and IGF1 while preventing filter clogging and reducing the need for filter replacement, allowing for efficient filtration and maintaining high growth factor concentrations, thus enhancing the operability of plasma processing.
Smart Images

Figure JP2024018431_05122024_PF_FP_ABST
Abstract
Description
Method for producing cell-free plasma or serum
[0001] The present invention relates to a method for producing cell-free plasma or serum, and more specifically to a method for producing cell-free plasma or serum enriched in VEGF or IGF1.
[0002] Several companies already offer blood processing services, including fractionation and purification of plasma from whole blood and subsequent freeze-drying. Plasma contains large amounts of growth factors such as PDGF-BB, VEGF, and IGF, and these processed products are used in treatments (such as knee joint treatment in the orthopedic field and hair loss treatment in the AGA field). These services are performed using acellular processed products that do not contain cells. Therefore, there is a demand for the production of cell-free plasma or serum that is enriched with growth factors such as VEGF and IGF1.
[0003] Patent Document 1 discloses an invention that provides a growth factor mixture that can be stored for a long period of time and a method for producing the same, which discloses a method for preparing a growth factor mixture from blood, which includes the steps of separating platelet-rich plasma from blood, removing cells from the platelet-rich plasma to obtain cell-free plasma, and freeze-drying the cell-free plasma to obtain the growth factor mixture. However, Patent Document 1 does not mention ultrasonic disruption treatment.
[0004] Patent Document 2 describes a method for preparing a particulate freeze-dried platelet lysate composition, the method comprising the steps of obtaining a platelet source containing platelets and a fluid carrier; lysing the platelets to form a plurality of lysates; filtering the plurality of lysates after lysis to remove cellular debris; and freeze-drying the plurality of lysates to form a particulate freeze-dried platelet lysate composition having released concentrations of available growth factors, cytokines, and chemokines, and the lysing step includes sonication of the platelet source. However, the examples in Patent Document 2 note that sonication, filtration, etc., can be used instead of or in addition to the freeze-thaw cycle described herein to lyse or collect platelets, but only abstractly suggest sonication and do not disclose the results of actual sonication. Furthermore, the examples in Patent Document 2 examine the contents of various growth factors, but do not examine the contents of VEGF or IGF1.
[0005] Patent Document 3 discloses an invention aimed at providing a serum preparation apparatus capable of simultaneously obtaining a large amount of serum capable of exhibiting high culture efficiency regardless of the freshness of the blood used, and the serum preparation apparatus is for preparing serum from blood containing at least platelets, and includes a blood reservoir for storing the blood, an ultrasonic oscillator housing provided in the blood reservoir and capable of housing an ultrasonic oscillator that generates ultrasonic waves, and a component housing connected to the blood reservoir in a sterile and airtight manner and for storing serum separated from the blood stored in the blood reservoir. However, the examples in Patent Document 3 only quantify TGF-β1 and PDGF-BB, and do not examine the contents of VEGF and IGF1.
[0006] Patent Literature 4 discloses an embodiment of a device, system, and method for producing an adjusted autologous platelet solution at a patient's bedside for simultaneous reinfusion into the patient, the device comprising: a housing; an inlet port into the housing for providing an inflow of a platelet-containing solution; a lysis / activation chamber fluidly connected to the inlet port and positioned within the housing, wherein one or more platelets in the platelet-containing solution flowing into the device are lysed or activated in the lysis / activation chamber, thereby producing an adjusted solution; and an outlet port fluidly connected to the lysis / activation chamber and providing the adjusted solution, which is removed through an outlet port. Patent Literature 4 also discloses that the device further comprises at least one acoustic transducer within the housing, the acoustic transducer mechanically coupled to the lysis / activation chamber and configured to pass acoustic energy through the lysis / activation chamber to cause ultrasonic lysis or activation of one or more platelets in the platelet-containing solution within the lysis / activation chamber. In the examples of Patent Document 4, the protein concentrations of TGF-β and VEGF growth factors are compared. However, the examples of Patent Document 4 do not disclose examples in which ultrasonic treatment was actually performed, and do not compare the protein concentrations of TGF-β and VEGF growth factors as examples in which ultrasonic treatment was actually performed.
[0007] Japanese Patent Application Laid-Open No. 2019-178116 Japanese Patent Application Laid-Open No. 2018-517771 Japanese Patent Application Laid-Open No. 2013-209409 Japanese Patent Application Laid-Open No. 2016-504165
[0008] Thus, the use of ultrasonic treatment as a method for concentrating growth factors has been proposed abstractly without any support from actual experimental results. However, according to the results of actual experiments, it has been found that, as shown in the Examples below, ultrasonic treatment of VEGF, among growth factors, does not concentrate VEGF but rather reduces the amount of VEGF, and a similar tendency has been observed for IGF1.
[0009] Because plasma components can be easily recovered by centrifugation, there is little knowledge about processing them to increase the amount of growth factors. Furthermore, additives such as reagents are preferably avoided as much as possible for safety reasons. Furthermore, because the plasma fraction obtained after centrifugation contains various protein components, clogging is often observed during acellular processing steps such as filtration. These issues pose challenges for plasma processing services.
[0010] Therefore, an object of the present invention is to provide a method for producing cell-free plasma or serum enriched with VEGF or IGF1 with excellent operability, such as by preventing clogging during filter filtration, enabling filtration to be performed in a short time, and eliminating the need for filter replacement.
[0011] After extensive research, the present inventors have unexpectedly found that cell-free plasma or serum enriched with VEGF or IGF1 can be produced with excellent operability by a method comprising the steps of: performing ultrasonic disruption at an output of 5 W to 500 W to obtain post-sonication plasma or serum; and removing cells from the obtained post-sonication plasma or serum to obtain cell-free plasma or serum. Considering that it has been recognized that, among growth factors, cell-free plasma or serum enriched with VEGF or IGF1 cannot be produced by ultrasonication, and that ultrasonication actually reduces the content of these factors in cell-free plasma or serum, this finding made by the present inventors is extremely unexpected.
[0012] That is, the present invention provides the following. [Aspect A-1] A method for producing cell-free plasma or serum enriched with VEGF or IGF1, comprising the steps of sonicating plasma or serum at an output of 5 W to 500 W to obtain sonicated plasma or serum, and removing cells from the sonicated plasma or serum to obtain cell-free plasma or serum. [Aspect A-2] The production method according to Aspect A-1, wherein the output for the sonication is 7 W to 100 W. [Aspect A-3] The production method according to Aspect A-1, wherein the sonication time is 5 seconds to 30 minutes. [Aspect A-4] The production method according to Aspect A-1, wherein the sonication is performed once, or in two to six separate steps. [Aspect A-5] The production method according to Aspect A-1, wherein the sonication is performed using a tip or cup horn. [Aspect A-6] The production method according to Aspect A-1, wherein the step of obtaining cell-free plasma or serum includes the step of removing cells using a filter. [Aspect A-7] The manufacturing method according to Aspect A-6, wherein the filter is a membrane filter having a pore size of 0.1 μm to 1 μm. [Aspect A-8] The manufacturing method according to Aspect A-1, wherein the step of obtaining cell-free plasma or serum includes a step of removing cells by centrifugation through a filter. [Aspect A-9] The manufacturing method according to Aspect A-8, wherein the rotation speed of the centrifugation is 500 rpm to 4500 rpm. [Aspect A-10] The manufacturing method according to Aspect A-8, wherein the centrifugation time is 1 minute to 30 minutes. [Aspect A-11] The manufacturing method according to Aspect A-1, wherein the plasma or serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood. [Aspect A-12] The manufacturing method according to Aspect A-11, wherein the rotation speed of the centrifugation is 500 to 4000 rpm. [Aspect A-13] The manufacturing method according to Aspect A-11, wherein the centrifugation time is 1 minute to 30 minutes. [Aspect A-14] The manufacturing method according to Aspect A-11, wherein the temperature during centrifugation is 4° C. to 40° C. [Aspect A-15] The manufacturing method according to claim 1, wherein the blood from which the plasma or serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W is derived is stored at 0° C. to 10° C. for 0 minutes to 144 hours after collection from a living body until treatment to obtain the plasma or serum.[Aspect A-16] The manufacturing method according to Aspect A-1, wherein the plasma to be sonicated at an output of 5 W to 500 W is obtained from blood to which an anticoagulant has been added after collection from a living body. [Aspect A-17] The manufacturing method according to Aspect A-16, wherein the anticoagulant is heparin salt, citric acid, or a citric acid derivative. [Aspect A-18] The manufacturing method according to Aspect A-1, wherein the serum to be sonicated at an output of 5 W to 500 W is obtained from blood to which an anticoagulant has been added after collection from a living body. [Aspect A-19] The manufacturing method according to Aspect A-1, wherein the cell-free plasma or serum enriched with VEGF or IGF1 is a lyophilized product. [Aspect A-20] Cell-free plasma or serum produced by the manufacturing method according to any one of Aspects A-1 to A-19. [Aspect A-21] A method for producing a processed plasma or serum product to produce cell-free plasma or serum enriched with VEGF or IGF1, the method comprising the step of sonicating the plasma or serum at an output of 5 W to 500 W to obtain a processed plasma or serum product. [Aspect B-1] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, the method comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 100 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the obtained post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum. [Aspect B-2] The method according to Aspect B-1, wherein the output for sonication is 7 W to 100 W. [Aspect B-3] The method according to Aspect B-1, wherein the sonication time is 5 seconds to 30 minutes. [Aspect B-4] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the resulting post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the sonication is performed once or in two to six separate steps.[Aspect B-5] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the steps of: sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum; and removing cells from the post-sonication plasma (excluding platelet-rich plasma) or serum obtained, wherein the sonication is performed using a tip or cup horn. [Aspect B-6] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched in VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the obtained post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the step of obtaining the cell-free plasma (excluding platelet-rich plasma) or serum comprises removing cells using a filter. [Aspect B-7] The production method according to Aspect B-6, wherein the filter is a membrane filter with a pore size of 0.1 μm to 1 μm. [Aspect B-8] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched in VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the obtained post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the step of obtaining the cell-free plasma (excluding platelet-rich plasma) or serum comprises removing cells by centrifugation through a filter. [Aspect B-9] The production method according to Aspect B-8, wherein the rotation speed of the centrifugation is 500 rpm to 4500 rpm. [Aspect B-10] The production method according to Aspect B-8, wherein the centrifugation time is 1 minute to 30 minutes.[Aspect B-11] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the resulting post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the plasma (excluding platelet-rich plasma) or serum to be sonicated at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood, and the centrifugation speed is 500 to 4,000 rpm. Aspect B-12 is a method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the resulting post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the plasma (excluding platelet-rich plasma) or serum sonicated at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood, and the centrifugation time is 1 minute to 30 minutes. Aspect B-13 is a method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain post-sonication plasma (excluding platelet-rich plasma) or serum, and removing cells from the resulting post-sonication plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the plasma (excluding platelet-rich plasma) or serum to be sonicated at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood, and the centrifugation is carried out at a temperature of 4°C to 40°C.[Aspect B-14] A method for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the steps of sonicating plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain sonicated plasma (excluding platelet-rich plasma) or serum, and removing cells from the sonicated plasma (excluding platelet-rich plasma) or serum to obtain cell-free plasma (excluding platelet-rich plasma) or serum, wherein the blood from which the plasma (excluding platelet-rich plasma) or serum is derived that is sonicated at an output of 5 W to 500 W has been stored at 0°C to 10°C for 0 minutes to 144 hours after collection from a living body until the treatment to obtain the plasma (excluding platelet-rich plasma) or serum. [Aspect B-15] The production method according to Aspect B-1, wherein the plasma (excluding platelet-rich plasma) that is sonicated at an output of 5 W to 100 W is obtained from blood to which an anticoagulant has been added after collection from a living body. [Aspect B-16] The manufacturing method according to Aspect B-15, wherein the anticoagulant is a heparin salt, citric acid, or a citric acid derivative. [Aspect B-17] The manufacturing method according to Aspect B-1, wherein the serum to be sonicated at an output of 5 W to 100 W is obtained from blood to which a coagulant has been added after collection from a living body. [Aspect B-18] The manufacturing method according to Aspect B-1, wherein the cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1 is a freeze-dried product. [Aspect B-19] Cell-free plasma (excluding platelet-rich plasma) or serum produced by the manufacturing method according to any one of Aspects B-1 to B-18. [Aspect B-20] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, the method comprising the step of subjecting plasma (excluding platelet-rich plasma) or serum to ultrasonic disruption at an output of 5 W to 100 W to obtain the processed product of plasma (excluding platelet-rich plasma) or serum.[Aspect B-21] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the step of sonicating the plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain a processed product of plasma (excluding platelet-rich plasma) or serum, wherein the sonication is performed in a single step or in two to six separate steps. [Aspect B-22] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, comprising the step of sonicating the plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain a processed product of plasma (excluding platelet-rich plasma) or serum, wherein the sonication is performed using a tip or cup horn. [Aspect B-23] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, the method comprising the step of sonicating the plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain a processed product of plasma (excluding platelet-rich plasma) or serum, wherein the plasma (excluding platelet-rich plasma) or serum sonicated at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood, and the centrifugation speed is 500 to 4,000 rpm. [Aspect B-24] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, the method comprising a step of sonicating the plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain a processed product of plasma (excluding platelet-rich plasma) or serum, wherein the plasma (excluding platelet-rich plasma) or serum sonicated at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood, and the centrifugation time is 1 minute to 30 minutes.[Aspect B-25] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, the method comprising the step of sonicating the plasma (excluding platelet-rich plasma) or serum at an output of 5 W to 500 W to obtain a processed product of plasma (excluding platelet-rich plasma) or serum, wherein the plasma (excluding platelet-rich plasma) or serum sonicated at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood, and the temperature during the centrifugation is 4°C to 40°C. [Aspect B-26] A method for producing a processed product of plasma (excluding platelet-rich plasma) or serum for producing cell-free plasma (excluding platelet-rich plasma) or serum enriched with VEGF or IGF1, the method comprising a step of subjecting plasma (excluding platelet-rich plasma) or serum to ultrasonic disruption at an output of 5 W to 500 W to obtain a processed product of plasma (excluding platelet-rich plasma) or serum, wherein the blood from which the plasma (excluding platelet-rich plasma) or serum to be ultrasonicated at an output of 5 W to 500 W is derived has been stored at 0°C to 10°C for 0 minutes to 144 hours from the time of collection from a living body until the time of treatment to obtain the plasma (excluding platelet-rich plasma) or serum.
[0013] According to a more specific embodiment of the production method of the present invention, cell-free plasma or serum enriched with VEGF or IGF1 can be produced with excellent operability, such as by preventing clogging during filter filtration, allowing filtration to be performed in a short time, and eliminating the need for filter replacement. This is presumably because the ultrasonic disruption treatment at an output of 5 W to 500 W eliminates the problem of protein complexes and other contaminants present in the plasma or serum fraction after centrifugation causing filter clogging and complicating subsequent processing, thereby reducing the concentration of VEGF or IGF1.
[0014] Figure 1 is a graph showing the results of ELISA analysis of VEGF concentrations in a sample sonicated at 0 W (untreated) (condition 1), a sample sonicated three times for 10 seconds at 10 W (condition 4), and a sample sonicated three times for 10 seconds at 2 W (condition 5). Figure 2 is a graph showing the results of ELISA analysis of IGF1 concentrations in a sample sonicated at 0 W (untreated) (condition 1), a sample sonicated three times for 10 seconds at 10 W (condition 4), and a sample sonicated three times for 10 seconds at 2 W (condition 5).
[0015] The present invention provides a method for producing cell-free plasma or serum enriched in VEGF or IGF1, comprising the steps of: sonicating plasma or serum at an output of 5 W to 500 W to obtain sonicated plasma or serum; and removing cells from the sonicated plasma or serum to obtain cell-free plasma or serum.
[0016] The output in the ultrasonic disruption treatment is preferably 5W to 500W, preferably 7W to 500W, preferably 10W to 500W, more preferably 5W to 400W, more preferably 7W to 400W, more preferably 10W to 400W, even more preferably 5W to 300W, even more preferably 7W to 300W, even more preferably 10W to 300W, even more preferably 5W to 200W, even more preferably 7W to 200W, even more preferably 10W to 200W, even more preferably 5W to 100W, even more preferably 7W to 100W, even more preferably 10W to 100W. The output power in the ultrasonic disruption treatment may be, for example, 5 W or more, 6 W or more, 7 W or more, 8 W or more, 9 W or more, 10 W or more, 20 W or more, 30 W or more, 40 W or more, 50 W or more, 60 W or more, 70 W or more, 80 W or more, 90 W or more, 100 W or more, 110 W or more, 120 W or more, 130 W or more, 140 W or more, 150 W or more, 160 W or more, 170 W or more, 180 W or more, 190 W or more, 200 W or more, 210 W or more, 220 W or more, or 230 W or more. , 240W or more, 250W or more, 260W or more, 270W or more, 280W or more, 290W or more, 300W or more, 310W or more, 320W or more, 330W or more, 340W or more, 350W or more, 360W or more, 370W or more, 380W or more, 390W or more, 400W or more, 410W or more, 420W or more, 430W or more, 440W or more, 450W or more, 460W or more, 470W or more, 480W or more, 490W or more, or 500W or more.The output in the ultrasonic disruption treatment is, for example, 500W or less, 490W or less, 480W or less, 470W or less, 460W or less, 450W or less, 440W or less, 430W or less, 420W or less, 410W or less, 400W or less, 390W or less, 380W or less, 370W or less, 360W or less, 350W or less, 340W or less, 330W or less, 320W or less, 310W or less, 300W or less, 290W or less, 280W or less, 270W or less, 260W or less, 2 50W or less, 240W or less, 230W or less, 220W or less, 210W or less, 200W or less, 190W or less, 180W or less, 170W or less, 160W or less, 150W or less, 140W or less, 130W or less, 120W or less, 110W or less, 100W or less, 90W or less, 80W or less, 70W or less, 60W or less, 50W or less, 40W or less, 30W or less, 20W or less, 10W or less, 9W or less, 8W or less, 7W or less, 6W or less, or 5W or less.
[0017] The ultrasonic disruption time is preferably 1 second to 45 minutes, more preferably 1 second to 30 minutes, more preferably 5 seconds to 30 minutes, even more preferably 10 seconds to 30 minutes, even more preferably 1 second to 10 minutes, even more preferably 5 seconds to 10 minutes, even more preferably 10 seconds to 10 minutes, even more preferably 1 second to 5 minutes, even more preferably 5 seconds to 5 minutes, even more preferably 10 seconds to 5 minutes. The ultrasonic disruption time may be, for example, 1 second to 1 minute, 5 seconds to 1 minute, 10 seconds to 1 minute, 1 second to 40 seconds, 5 seconds to 40 seconds, or 10 seconds to 40 seconds. The time for ultrasonic disruption treatment may be, for example, 1 second or more, 2 seconds or more, 3 seconds or more, 4 seconds or more, 5 seconds or more, 6 seconds or more, 7 seconds or more, 8 seconds or more, 9 seconds or more, 10 seconds or more, 20 seconds or more, 30 seconds or more, 40 seconds or more, 50 seconds or more, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, 10 minutes or more, 11 minutes or more, 12 minutes or more, 13 minutes or more, 14 minutes or more, 15 minutes or more, 16 minutes or more, 17 minutes or more, 18 minutes or more, 19 minutes or more, 20 minutes or more, 21 minutes or more, 22 minutes or more, 23 minutes or more, 24 minutes or more, 25 minutes or more, 26 minutes or more, 27 minutes or more, 28 minutes or more, 29 minutes or more, 30 minutes or more, 31 minutes or more, 32 minutes or more, 33 minutes or more, 34 minutes or more, 35 minutes or more, 36 minutes or more, 37 minutes or more, 38 minutes or more, 39 minutes or more, 40 minutes or more, 41 minutes or more, 42 minutes or more, 43 minutes or more, 44 minutes or more, or 45 minutes or more. The ultrasonic disruption treatment time may be, for example, 45 minutes or less, 44 minutes or less, 43 minutes or less, 42 minutes or less, 41 minutes or less, 40 minutes or less, 39 minutes or less, 38 minutes or less, 37 minutes or less, 36 minutes or less, 35 minutes or less, 34 minutes or less, 33 minutes or less, 32 minutes or less, 31 minutes or less, 30 minutes or less, 29 minutes or less, 28 minutes or less, 27 minutes or less, 26 minutes or less, 25 minutes or less, 24 minutes or less, 23 minutes or less, 22 minutes or less, 21 minutes or less, 20 minutes or less, 19 minutes or less, 18 minutes or less, 17 minutes or less, 16 minutes or less, 15 minutes or less, 14 minutes or less, 13 minutes or less, 12 minutes or less, 11 minutes or less, 10 minutes or less, 9 minutes or less, 8 minutes or less, 7 minutes or less, 6 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less, 1 minute or less, 50 seconds or less, 40 seconds or less, 30 seconds or less, 20 seconds or less, 10 seconds or less, 9 seconds or less, 8 seconds or less, 7 seconds or less, 6 seconds or less, 5 seconds or less, 4 seconds or less, 3 seconds or less, 2 seconds or less, or 1 second or less.When the ultrasonic disruption treatment is carried out in multiple steps, the ultrasonic disruption treatment time refers to the total time of the multiple ultrasonic disruption treatments.
[0018] The ultrasonic disruption treatment may be carried out in one go or in separate runs, preferably in 2 to 10 runs, more preferably in 2 to 8 runs, even more preferably in 2 to 6 runs, and even more preferably in 2 to 4 runs.
[0019] The ultrasonic disruption treatment is not limited, and any ultrasonic disruption treatment can be used, including known ultrasonic disruption treatments. However, tip-type ultrasonic disruption (e.g., Tommy Seiko, UD-100) or cup horn-type ultrasonic disruption (e.g., Tommy Seiko, UD-211) ultrasonic disruption treatments are preferred. Examples of tip-type ultrasonic disruption treatments include those in which an ultrasonic generator (a thin rod) is directly inserted into the specimen. Therefore, efficient treatment can be achieved at a low wattage, such as 1 W to 50 W. The output power of tip-type ultrasonic disruption treatments is preferably 5 W to 100 W, preferably 7 W to 100 W, more preferably 5 W to 90 W, more preferably 7 W to 90 W, even more preferably 5 W to 70 W, even more preferably 7 W to 70 W, even more preferably 5 W to 50 W, even more preferably 7 W to 50 W, even more preferably 5 W to 30 W, even more preferably 7 W to 30 W. An example of a cup horn type is one in which the entire water bath is ultrasonically vibrated to process a tube containing a sample immersed therein, even beyond the wall of the tube. Therefore, a high output of 100 W to 500 W is required. The output in the cup horn type ultrasonic disruption treatment is preferably 10 W to 500 W, more preferably 20 W to 400 W, even more preferably 30 W to 300 W, even more preferably 40 W to 250 W, and even more preferably 50 W to 200 W. The ultrasonic disruption treatment can be performed, for example, under sterilization or non-sterilization.
[0020] Examples of processes for removing cells from plasma or serum after ultrasonic disruption to obtain cell-free plasma or serum include, for example, heat treatment, acid treatment, and filtering to remove cells. Among these, filtering is preferred because it reduces the risk of denaturing growth factors. The filter used is not limited as long as it can remove blood cells. However, since the minimum size of blood cells is approximately 2 μm, the same as platelets, a membrane filter with a pore size of 1 μm or less, more preferably 0.7 μm or less, and even more preferably 0.5 μm or less can be used. While there is no lower limit for the pore size of the membrane filter, excessively small filters increase the risk of clogging. Therefore, a pore size of 0.1 μm or more is preferred, and 0.2 μm or more is more preferred. Among commercially available membrane filters that meet this range, membrane filters with a pore size of approximately 0.2 μm and approximately 0.45 μm are available, and both can be used in the present invention. An example of a filter is a filter that can be attached to a syringe and manually pressed to filter, such as Millex GV (SLGVR33RS) manufactured by Millipore.
[0021] Furthermore, the step of removing cells from the plasma or serum after ultrasonic disruption to obtain cell-free plasma or serum preferably includes a step of removing cells by centrifugation through a filter. Examples of the filter include the same filters as those described above. The rotation speed of the centrifugation is preferably 500 rpm to 4500 rpm, more preferably 750 rpm to 4000 rpm, even more preferably 1000 rpm to 3000 rpm, and even more preferably 1500 rpm to 2000 rpm. The rotation speed of the centrifugation treatment may be, for example, 500 rpm or more, 600 rpm or more, 700 rpm or more, 800 rpm or more, 900 rpm or more, 1000 rpm or more, 1100 rpm or more, 1200 rpm or more, 1300 rpm or more, 1400 rpm or more, 1500 rpm or more, 1600 rpm or more, 1700 rpm or more, 1800 rpm or more, 1900 rpm or more, 2000 rpm or more, 2100 rpm or more, 2200 rpm or more, 2300 rpm or more, 2400 rpm or more, 25 00 rpm or more, 2600 rpm or more, 2700 rpm or more, 2800 rpm or more, 2900 rpm or more, 3000 rpm or more, 3100 rpm or more, 3200 rpm or more, 3300 rpm or more, 3400 rpm or more, 3500 rpm or more, 3600 rpm or more, 3700 rpm or more, 3800 rpm or more, 3900 rpm or more, 4000 rpm or more, 4100 rpm or more, 4200 rpm or more, 4300 rpm or more, 4400 rpm or more, or 4500 rpm or more.The rotation speed of the centrifugation treatment is, for example, 4500 rpm or less, 4400 rpm or less, 4300 rpm or less, 4200 rpm or less, 4100 rpm or less, 4000 rpm or less, 3900 rpm or less, 3800 rpm or less, 3700 rpm or less, 3600 rpm or less, 3500 rpm or less, 3400 rpm or less, 3300 rpm or less, 3200 rpm or less, 3100 rpm or less, 3000 rpm or less, 2900 rpm or less, 2800 rpm or less, 2700 rpm or less, 2600 rpm or less. The centrifugation time is preferably 1 to 30 minutes, more preferably 3 to 20 minutes, even more preferably 4 to 15 minutes, and even more preferably 5 to 10 minutes. The time for centrifugation is, for example, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, 10 minutes or more, 11 minutes or more, 12 minutes or more, 13 minutes or more, 14 minutes or more, 15 minutes or more, 16 minutes or more, 17 minutes or more, 18 minutes or more, 19 minutes or more, 20 minutes or more, 21 minutes or more, 22 minutes or more, 23 minutes or more, 24 minutes or more, 25 minutes or more, 26 minutes or more, 27 minutes or more, 28 minutes or more, 29 minutes or more, or 30 minutes or more. The time for centrifugation is, for example, 30 minutes or less, 29 minutes or less, 28 minutes or less, 27 minutes or less, 26 minutes or less, 25 minutes or less, 24 minutes or less, 23 minutes or less, 22 minutes or less, 21 minutes or less, 20 minutes or less, 19 minutes or less, 18 minutes or less, 17 minutes or less, 16 minutes or less, 15 minutes or less, 14 minutes or less, 13 minutes or less, 12 minutes or less, 11 minutes or less, 10 minutes or less, 9 minutes or less, 8 minutes or less, 7 minutes or less, 6 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less, or 1 minute or less.
[0022] In the production method of the present invention, the plasma or serum to be sonicated at an output of 5 W to 500 W is preferably derived from a supernatant recovered by centrifuging blood, more preferably derived from a supernatant recovered by centrifuging blood, and does not contain precipitates obtained by centrifuging blood or a supernatant derived from blood (e.g., a supernatant obtained by centrifugation), and even more preferably a supernatant recovered by centrifuging blood. Here, the rotation speed of the centrifugation is preferably 500 to 4000 rpm, more preferably 1000 to 4000 rpm, even more preferably 1000 to 2000 rpm, and even more preferably 1000 to 1500 rpm. The rotation speed of the centrifugation process is, for example, 500 rpm or more, 600 rpm or more, 700 rpm or more, 800 rpm or more, 900 rpm or more, 1000 rpm or more, 1100 rpm or more, 1200 rpm or more, 1300 rpm or more, 1400 rpm or more, 1500 rpm or more, 1600 rpm or more, 1700 rpm or more, 1800 rpm or more, 1900 rpm or more, 2000 rpm or more, 2100 rpm or more, 2200 rpm or more. or more, 2300 rpm or more, 2400 rpm or more, 2500 rpm or more, 2600 rpm or more, 2700 rpm or more, 2800 rpm or more, 2900 rpm or more, 3000 rpm or more, 3100 rpm or more, 3200 rpm or more, 3300 rpm or more, 3400 rpm or more, 3500 rpm or more, 3600 rpm or more, 3700 rpm or more, 3800 rpm or more, 3900 rpm or more, or 4000 rpm or more.The rotation speed of the centrifugation treatment may be, for example, 4000 rpm or less, 3900 rpm or less, 3800 rpm or less, 3700 rpm or less, 3600 rpm or less, 3500 rpm or less, 3400 rpm or less, 3300 rpm or less, 3200 rpm or less, 3100 rpm or less, 3000 rpm or less, 2900 rpm or less, 2800 rpm or less, 2700 rpm or less, 2600 rpm or less, 2500 rpm or less, 2400 rpm or less, 23 The preferred centrifugation speed is 1000 rpm or less, 2200 rpm or less, 2100 rpm or less, 2000 rpm or less, 1900 rpm or less, 1800 rpm or less, 1700 rpm or less, 1600 rpm or less, 1500 rpm or less, 1400 rpm or less, 1300 rpm or less, 1200 rpm or less, 1100 rpm or less, 1000 rpm or less, 900 rpm or less, 800 rpm or less, 700 rpm or less, 600 rpm or less, or 500 rpm or less. The centrifugation time is preferably 1 to 30 minutes, more preferably 5 to 30 minutes, and even more preferably 5 to 15 minutes. The time for centrifugation is, for example, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, 10 minutes or more, 11 minutes or more, 12 minutes or more, 13 minutes or more, 14 minutes or more, 15 minutes or more, 16 minutes or more, 17 minutes or more, 18 minutes or more, 19 minutes or more, 20 minutes or more, 21 minutes or more, 22 minutes or more, 23 minutes or more, 24 minutes or more, 25 minutes or more, 26 minutes or more, 27 minutes or more, 28 minutes or more, 29 minutes or more, or 30 minutes or more. The time for centrifugation is, for example, 30 minutes or less, 29 minutes or less, 28 minutes or less, 27 minutes or less, 26 minutes or less, 25 minutes or less, 24 minutes or less, 23 minutes or less, 22 minutes or less, 21 minutes or less, 20 minutes or less, 19 minutes or less, 18 minutes or less, 17 minutes or less, 16 minutes or less, 15 minutes or less, 14 minutes or less, 13 minutes or less, 12 minutes or less, 11 minutes or less, 10 minutes or less, 9 minutes or less, 8 minutes or less, 7 minutes or less, 6 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less, or 1 minute or less. The temperature during centrifugation is preferably 4°C to 40°C, more preferably 4°C to 30°C, and even more preferably 4°C to 25°C. The temperature during centrifugation may be 10°C to 40°C, 15°C to 30°C, or 20°C to 25°C.The temperature during centrifugation is, for example, 4°C or higher, 5°C or higher, 6°C or higher, 7°C or higher, 8°C or higher, 9°C or higher, 10°C or higher, 11°C or higher, 12°C or higher, 13°C or higher, 14°C or higher, 15°C or higher, 16°C or higher, 17°C or higher, 18°C or higher, 19°C or higher, 20°C or higher, 21°C or higher, 22°C or higher, 23°C or higher, 24°C or higher, 25°C or higher, 26°C or higher, 27°C or higher, 28°C or higher, 29°C or higher, 30°C or higher, 31°C or higher, 32°C or higher, 33°C or higher, 34°C or higher, 35°C or higher, 36°C or higher, 37°C or higher, 38°C or higher, 39°C or higher, or 40°C or higher. The temperature during centrifugation is, for example, 40° C. or less, 39° C. or less, 38° C. or less, 37° C. or less, 36° C. or less, 35° C. or less, 34° C. or less, 33° C. or less, 32° C. or less, 31° C. or less, 30° C. or less, 29° C. or less, 28° C. or less, 27° C. or less, 26° C. or less, 25° C. or less, 24° C. or less, 23° C. or less, 22° C. or less, 21° C. or less, 20° C. or less, 19° C. or less, 18° C. or less, 17° C. or less, 16° C. or less, 15° C. or less, 14° C. or less, 13° C. or less, 12° C. or less, 11° C. or less, 10° C. or less, 9° C. or less, 8° C. or less, 7° C. or less, 6° C. or less, 5° C. or less, or 4° C. or less. In the production method of the present invention, the plasma or serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W may not be, for example, platelet-rich plasma. That is, in the production method of the present invention, the plasma or serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W may, for example, exclude platelet-rich plasma. Platelet-rich plasma is also called platelet-rich plasma. More specifically, the plasma or serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W in the production method of the present invention contains cells.
[0023] The blood from which plasma or serum is to be subjected to ultrasonic disruption at an output of 5 W to 500 W, such as the blood to be centrifuged as described above, is preferably stored for 0 minutes from collection from a living body until treatment to obtain plasma or serum, such as centrifugation, but may be stored for 1 minute to 144 hours, more preferably 2 minutes to 120 hours, even more preferably 3 minutes to 96 hours, and even more preferably 4 minutes to 72 hours. The storage time may be, for example, 10 seconds or more, 20 seconds or more, 30 seconds or more, 40 seconds or more, 50 seconds or more, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, 10 minutes or more, 20 minutes or more, 30 minutes or more, 40 minutes or more, 50 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 6 hours or more, 7 hours or more, 8 hours or more, 9 hours or more, 10 hours or more, 11 hours or more, 12 hours or more, 1 hour or more, 3 hours or more, 14 hours or more, 15 hours or more, 16 hours or more, 17 hours or more, 18 hours or more, 19 hours or more, 20 hours or more, 21 hours or more, 22 hours or more, 23 hours or more, 24 hours or more, 25 hours or more, 26 hours or more , 27 hours or more, 28 hours or more, 29 hours or more, 30 hours or more, 31 hours or more, 32 hours or more, 33 hours or more, 34 hours or more, 35 hours or more, 36 hours or more, 37 hours or more, 38 hours or more, 39 hours or more, 40 hours or more Above, 41 hours or more, 42 hours or more, 43 hours or more, 44 hours or more, 45 hours or more, 46 hours or more, 47 hours or more, 48 hours or more, 49 hours or more, 50 hours or more, 51 hours or more, 52 hours or more, 53 hours or more, 54 hours or more, 55 hours or more, 56 hours or more, 57 hours or more, 58 hours or more, 59 hours or more, 60 hours or more, 61 hours or more, 62 hours or more, 63 hours or more, 64 hours or more, 65 hours or more, 66 hours or more, 67 hours or more, 68 hours or more, 69 hours or more, 70 hours or more, 71 hours or more, 72 hours or more, 73 hours or more, 74 hours or more, 75 hours or more, 76 hours or more, 77 hours or more, 78 hours or more, 79 hours or more, 80 hours or more, 81 hours or more, 82 hours or more, 83 hours or more, 84 hours or more, 85 hours or more, 86 hours or more, 87 hours or more, 88 hours or more, 89 hours or more, 90 hours or more, 91 hours or more, 92 hours or more, 93 hours or more, 94 hours or more, 95 hours or more,96 hours or more, 97 hours or more, 98 hours or more, 99 hours or more, 100 hours or more, 101 hours or more, 102 hours or more, 103 hours or more, 104 hours or more, 105 hours or more, 106 hours or more, 107 hours or more, 108 hours or more, 109 hours or more, 110 hours or more, 111 hours or more, 112 hours or more, 113 hours or more, 114 hours or more, 115 hours or more, 116 hours or more, 117 hours or more, 118 hours or more, 119 hours or more, 120 hours or more, 121 hours or more, 122 hours or more, 123 hours or more, 124 hours or more, 125 hours or more, 126 hours or more, 127 hours or more, 128 hours or more, 129 hours or more, 130 hours or more, 131 hours or more, 132 hours or more, 133 hours or more, 134 hours or more, 135 hours or more, 136 hours or more, 137 hours or more, 138 hours or more, 139 hours or more, 140 hours or more, 141 hours or more, 142 hours or more, 143 hours or more, or 144 hours or more. The storage time is, for example, 144 hours or less, 143 hours or less, 142 hours or less, 141 hours or less, 140 hours or less, 139 hours or less, 138 hours or less, 137 hours or less, 136 hours or less, 135 hours or less, 134 hours or less, 133 hours or less, 132 hours or less, 131 hours or less, 130 hours or less, 129 hours or less, 128 hours or less, 127 hours or less, 126 hours or less, 125 hours or less, 124 hours or less, 123 hours or less, 122 hours or less, 121 hours or less, 120 hours or less, 119 hours or less, 118 hours or less, 117 hours or less, 116 hours or less, 115 hours or less, 114 hours or less, 113 hours or less, 112 hours or less, 111 hours or less, 110 hours or less, 109 hours or less, 116 hours or less, 115 hours or less, 114 hours or less, 113 hours or less, 112 hours or less, 111 hours or less, 110 hours or less, 119 hours or less, 128 hours or less, 127 hours or less, 126 hours or less, 125 hours or less, 124 hours or less, 123 hours or less, 122 hours or less, 121 hours or less, 120 hours or less, 119 hours or less, 118 hours or less, 117 hours or less, 116 hours or less, 115 hours or less, 114 hours or less, 113 hours or less, 112 hours or less, 111 hours or less, 110 hours or less 08 hours or less, 107 hours or less, 106 hours or less, 105 hours or less, 104 hours or less, 103 hours or less, 102 hours or less, 101 hours or less, 100 hours or less, 99 hours or less, 98 hours or less, 97 hours or less, 96 hours or less, 95 hours or less, 94 hours or less, 93 hours or less, 92 hours or less, 91 hours or less, 90 hours or less, 89 hours or less, 88 hours 87 hours or less, 86 hours or less, 85 hours or less, 84 hours or less, 83 hours or less, 82 hours or less, 81 hours or less, 80 hours or less, 79 hours or less, 78 hours or less, 77 hours or less, 76 hours or less, 75 hours or less, 74 hours or less, 73 hours or less, 72 hours or less, 71 hours or less, 70 hours or less, 69 hours or less, 68 hours or less, 67 hours or less,66 hours or less, 65 hours or less, 64 hours or less, 63 hours or less, 62 hours or less, 61 hours or less, 60 hours or less, 59 hours or less, 58 hours or less, 57 hours or less, 56 hours or less, 55 hours or less, 54 hours or less, 53 hours or less, 52 hours or less, 51 hours or less, 50 hours or less, 49 hours or less, 48 hours or less, 47 hours or less, 46 hours or less, 45 hours or less, 44 hours or less, 43 hours or less, 42 hours or less, 41 hours or less, 40 hours or less, 39 hours or less, 38 hours or less, 37 hours or less, 36 hours or less, 35 hours or less, 34 hours or less, 33 hours or less, 32 hours or less, 31 hours or less, 30 hours or less, 29 hours or less, 28 hours or less, 27 hours or less, 2 The duration is 6 hours or less, 25 hours or less, 24 hours or less, 23 hours or less, 22 hours or less, 21 hours or less, 20 hours or less, 19 hours or less, 18 hours or less, 17 hours or less, 16 hours or less, 15 hours or less, 14 hours or less, 13 hours or less, 12 hours or less, 11 hours or less, 10 hours or less, 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, 50 minutes or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 10 minutes or less, 9 minutes or less, 8 minutes or less, 7 minutes or less, 6 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less, 1 minute or less, 50 seconds or less, 40 seconds or less, 30 seconds or less, 20 seconds or less, or 10 seconds or less. The storage temperature is, for example, 0°C to 10°C, more preferably 2°C to 8°C, even more preferably 4°C to 6°C, and even more preferably 4°C to 5°C. The storage temperature is, for example, 0°C or higher, 1°C or higher, 2°C or higher, 3°C or higher, 4°C or higher, 5°C or higher, 6°C or higher, 7°C or higher, 8°C or higher, 9°C or higher, or 10°C or higher. The storage temperature is, for example, 10°C or lower, 9°C or lower, 8°C or lower, 7°C or lower, 6°C or lower, 5°C or lower, 4°C or lower, 3°C or lower, 2°C or lower, 1°C or lower, or 0°C or lower. The production method of the present invention does not undergo significant changes during storage and can meet the needs for transporting the blood sample. Here, the blood from which the plasma or serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W is derived is preferably blood to which an anticoagulant or a blood coagulant has been added. In this case, the start of the storage period may be the time when the anticoagulant or the blood coagulant is added. ,
[0024] In the production method of the present invention, the plasma to be sonicated at an output of 5 W to 500 W is preferably obtained from blood to which an anticoagulant has been added after collection from a living body. Examples of the anticoagulant include heparin salts such as sodium heparin; citric acid such as citric acid hydrate; citrate salts such as sodium citrate and sodium citrate hydrate, citric acid derivatives such as dextrose citrate; and EDTA salts such as EDTA-2Na and EDTA-2K.
[0025] In the production method of the present invention, the serum to be subjected to ultrasonic disruption at an output of 5 W to 500 W may be obtained by, for example, clot formation without using a blood coagulant, or may be obtained from blood to which a blood coagulant has been added after collection from a living body. Examples of blood coagulants include thrombin and fibrinogen.
[0026] The blood to which the anticoagulant or blood coagulant is added may be stored after collection from a living body and before the anticoagulant or blood coagulant is added. Here, the storage time is preferably 0 minutes to 72 hours, more preferably 0 minutes to 48 hours, even more preferably 0 minutes to 24 hours, and even more preferably 0 minutes to 1 hour. The storage time may be 1 minute to 72 hours, 1 minute to 48 hours, 1 minute to 24 hours, or 1 minute to 1 hour. The storage time may be, for example, 10 seconds or more, 20 seconds or more, 30 seconds or more, 40 seconds or more, 50 seconds or more, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, 10 minutes or more, 20 minutes or more, 30 minutes or more, 40 minutes or more, 50 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 6 hours or more, 7 hours or more, 8 hours or more, 9 hours or more, 10 hours or more, 11 hours or more, 12 hours or more, or 13 hours. 14 hours or more, 15 hours or more, 16 hours or more, 17 hours or more, 18 hours or more, 19 hours or more, 20 hours or more, 21 hours or more, 22 hours or more, 23 hours or more, 24 hours or more, 25 hours or more, 26 hours or more, 27 hours 28 hours or more, 29 hours or more, 30 hours or more, 31 hours or more, 32 hours or more, 33 hours or more, 34 hours or more, 35 hours or more, 36 hours or more, 37 hours or more, 38 hours or more, 39 hours or more, 40 hours or more, 41 hours or more Above, 42 hours or more, 43 hours or more, 44 hours or more, 45 hours or more, 46 hours or more, 47 hours or more, 48 hours or more, 49 hours or more, 50 hours or more, 51 hours or more, 52 hours or more, 53 hours or more, 54 hours or more, 55 hours or more, 56 hours or more, 57 hours or more, 58 hours or more, 59 hours or more, 60 hours or more, 61 hours or more, 62 hours or more, 63 hours or more, 64 hours or more, 65 hours or more, 66 hours or more, 67 hours or more, 68 hours or more, 69 hours or more , 70 hours or more, 71 hours or more, 72 hours or more, 73 hours or more, 74 hours or more, 75 hours or more, 76 hours or more, 77 hours or more, 78 hours or more, 79 hours or more, 80 hours or more, 81 hours or more, 82 hours or more, 83 hours or more, 84 hours or more, 85 hours or more, 86 hours or more, 87 hours or more, 88 hours or more, 89 hours or more, 90 hours or more, 91 hours or more, 92 hours or more, 93 hours or more, 94 hours or more, 95 hours or more, 96 hours or more, 97 hours or more,98 hours or more, 99 hours or more, 100 hours or more, 101 hours or more, 102 hours or more, 103 hours or more, 104 hours or more, 105 hours or more, 106 hours or more, 107 hours or more, 108 hours or more, 109 hours or more, 110 hours or more, 111 hours or more, 112 hours or more, 113 hours or more, 114 hours or more, 115 hours or more, 116 hours or more, 117 hours or more, 118 hours or more, 119 hours or more, 120 hours or more, 121 hours or more , 122 hours or more, 123 hours or more, 124 hours or more, 125 hours or more, 126 hours or more, 127 hours or more, 128 hours or more, 129 hours or more, 130 hours or more, 131 hours or more, 132 hours or more, 133 hours or more, 134 hours or more, 135 hours or more, 136 hours or more, 137 hours or more, 138 hours or more, 139 hours or more, 140 hours or more, 141 hours or more, 142 hours or more, 143 hours or more, or 144 hours or more. The storage time may be, for example, 144 hours or less, 143 hours or less, 142 hours or less, 141 hours or less, 140 hours or less, 139 hours or less, 138 hours or less, 137 hours or less, 136 hours or less, 135 hours or less, 134 hours or less, 133 hours or less, 132 hours or less, 131 hours or less, 130 hours or less, 129 hours or less, 128 hours or less, 127 hours or less, 126 hours or less, 125 hours or less, 124 hours or less, 123 hours or less, 122 hours or less, 121 hours or less, 120 hours or less, 119 hours or less, 118 hours or less, 117 hours or less, 116 hours or less, 115 hours or less, 114 hours or less, 113 hours or less, 112 hours or less, 111 hours or less, 110 hours or less, 109 hours or less, 108 hours or less, 107 hours or less, 106 hours or less, 105 hours or less, 104 hours or less, 103 hours or less, 102 hours or less, 101 hours or less, 100 hours or less, 99 hours or less, 98 hours or less, 97 hours or less, 96 hours or less, 95 hours or less, 94 hours or less, 93 hours or less, 92 hours or less, 91 hours or less, 90 hours or less, 89 hours or less, 88 hours or less, 87 hours or less , 86 hours or less, 85 hours or less, 84 hours or less, 83 hours or less, 82 hours or less, 81 hours or less, 80 hours or less, 79 hours or less, 78 hours or less, 77 hours or less, 76 hours or less, 75 hours or less, 74 hours or less, 73 hours or less, 72 hours or less, 71 hours or less, 70 hours or less, 69 hours or less, 68 hours or less, 67 hours or less, 66 hours or less, 65 hours or less,64 hours or less, 63 hours or less, 62 hours or less, 61 hours or less, 60 hours or less, 59 hours or less, 58 hours or less, 57 hours or less, 56 hours or less, 55 hours or less, 54 hours or less, 53 hours or less, 52 hours or less, 51 hours or less, 50 hours or less, 49 hours or less, 48 hours or less, 47 hours or less, 46 hours or less, 45 hours 44 hours or less, 43 hours or less, 42 hours or less, 41 hours or less, 40 hours or less, 39 hours or less, 38 hours or less, 37 hours or less, 36 hours or less, 35 hours or less, 34 hours or less, 33 hours or less, 32 hours or less, 31 hours or less, 30 hours or less, 29 hours or less, 28 hours or less, 27 hours or less, 26 hours or less, 2 The duration is 5 hours or less, 24 hours or less, 23 hours or less, 22 hours or less, 21 hours or less, 20 hours or less, 19 hours or less, 18 hours or less, 17 hours or less, 16 hours or less, 15 hours or less, 14 hours or less, 13 hours or less, 12 hours or less, 11 hours or less, 10 hours or less, 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, 50 minutes or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 10 minutes or less, 9 minutes or less, 8 minutes or less, 7 minutes or less, 6 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less, 1 minute or less, 50 seconds or less, 40 seconds or less, 30 seconds or less, 20 seconds or less, or 10 seconds or less. The storage temperature is preferably 0°C to 10°C, more preferably 1°C to 8°C, even more preferably 2°C to 6°C, and even more preferably 3°C to 5°C. The storage temperature is, for example, 0°C or higher, 1°C or higher, 2°C or higher, 3°C or higher, 4°C or higher, 5°C or higher, 6°C or higher, 7°C or higher, 8°C or higher, 9°C or higher, or 10°C or higher. The storage temperature is, for example, 10°C or lower, 9°C or lower, 8°C or lower, 7°C or lower, 6°C or lower, 5°C or lower, 4°C or lower, 3°C or lower, 2°C or lower, 1°C or lower, or 0°C or lower. The production method of the present invention does not undergo significant changes during storage at these temperatures, and can meet the needs for transporting blood as a sample.
[0027] The cell-free plasma or serum produced by the production method of the present invention may contain excipients, additives, buffers, salts for adjusting isotonicity, antioxidants, preservatives, drug stabilizers, etc. Examples of excipients include, but are not limited to, water, purified water, physiological saline, alcohol, glycerin, lactose, starch, glucose, dextrin, sucrose, precipitated silica, honey, rice starch, tragacanth, etc. Furthermore, the cell-free plasma or serum produced by the production method of the present invention may be lyophilized.
[0028] The cell-free plasma or serum produced by the production method of the present invention may be one that has undergone a cell removal step, and therefore the mere detection of cells does not negate the fact that the plasma or serum is cell-free. However, the cell-free plasma or serum produced by the production method of the present invention is preferably one in which no cells are detectable, and more preferably one in which cells have been completely removed.
[0029] Example 1: Approximately 40 mL of whole blood was collected from one adult male volunteer. The collected whole blood was placed in a heparin tube (BML, Inc.), a blood anticoagulant-containing tube, mixed by inversion, and then stored. The heparin tube contained the anticoagulant heparin sodium and ACD solution (components: sodium citrate hydrate, citric acid hydrate, and glucose). The tube was refrigerated overnight (approximately 16 hours) at 4°C in a constant temperature bath. After refrigeration, the tube was centrifuged (1300 rpm, 10 minutes, 24°C) to recover the supernatant plasma (approximately 20 mL). Using a non-sterile ultrasonic generator (ultrasonic homogenizer) (Tomy Seiko, Handy Sonic, UR-20P), the plasma was subjected to ultrasonic disruption at 0 W, 2 W, or 10 W output, three times for 10 seconds each, to obtain three types of samples. After ultrasonic disruption, the sample was transferred to a syringe and filtered through a 0.22 μm membrane filter to remove cellular components. This filtering process separated the remaining blood cells from the liquid (cell-free plasma) that passed through the filter. Approximately 18 mL of cell-free plasma was dispensed into nine vials (2 mL each) and stored frozen at -80°C to obtain samples.
[0030] The concentrations of growth factors VEGF and IGF1 in the obtained samples were analyzed by ELISA. The results for VEGF are shown in Figure 1, and the results for IGF1 are shown in Figure 2. In Figures 1 and 2, condition 1 is the result for a sample that was sonicated at 0 W (untreated). Condition 4 is the result for a sample that was sonicated three times for 10 seconds at 10 W. Condition 5 is the result for a sample that was sonicated three times for 10 seconds at 2 W.
[0031] As shown in Figures 1 and 2, when ultrasonic disruption is performed at an output of 2 W, for example, three times for 10 seconds at 2 W, the concentration of the cytokine VEGF is not increased, but rather decreased. However, quite surprisingly, when ultrasonic disruption is performed at an output of 10 W, for example, three times for 10 seconds at 10 W, the concentration of the cytokine VEGF is increased, and a similar tendency was observed for the concentration of the cytokine IGF1.
[0032] Furthermore, ultrasonic disruption enabled smooth filtration using a 0.22 μm filter, etc. That is, filtration required 15 seconds at 0 W, and sometimes the filter had to be replaced due to clogging, but filtration could be completed in 5 seconds at 2 W under the same conditions, and filtration could be completed in 1 second at 5 W. Furthermore, there was no need to replace the filter, and the time required for this process was significantly reduced.
Claims
1. A method for producing cell-free plasma or serum enriched with VEGF or IGF1, comprising the steps of: ultrasonically disrupting plasma or serum at an output of 5 W to 500 W to obtain post-sonication plasma or serum; and removing cells from the post-sonication plasma or serum to obtain cell-free plasma or serum.
2. The method according to claim 1, wherein the output of the ultrasonic disruption treatment is 7 W to 100 W.
3. The method according to claim 1, wherein the ultrasonic disruption treatment is carried out for 5 seconds to 30 minutes.
4. The method according to claim 1, wherein the ultrasonic disruption treatment is carried out once or in two to six separate steps.
5. The method according to claim 1, wherein the ultrasonic disruption treatment is by a tip or cup horn method.
6. The method according to claim 1, wherein the step of obtaining cell-free plasma or serum includes a step of removing cells through a filter.
7. The method according to claim 6, wherein the filter is a membrane filter having a pore size of 0.1 μm to 1 μm.
8. The method according to claim 1, wherein the step of obtaining cell-free plasma or serum comprises removing cells by centrifugation through a filter.
9. The method according to claim 8, wherein the rotation speed of the centrifugation treatment is 500 rpm to 4,500 rpm.
10. The method according to claim 8, wherein the centrifugation time is from 1 to 30 minutes.
11. The method according to claim 1, wherein the plasma or serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood.
12. The method according to claim 11, wherein the rotation speed of the centrifugation treatment is 500 to 4,000 rpm.
13. The method according to claim 11, wherein the centrifugation time is from 1 minute to 30 minutes.
14. The method according to claim 11, wherein the temperature during centrifugation is 4°C to 40°C.
15. The method according to claim 1, wherein the blood from which the plasma or serum is derived to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is stored at 0°C to 10°C for 0 minutes to 144 hours from the time of collection from a living body until the treatment to obtain the plasma or serum.
16. The method according to claim 1, wherein the plasma to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is obtained from blood to which an anticoagulant has been added after collection from a living body.
17. The process according to claim 16, wherein the anticoagulant is a heparin salt, citric acid or a citric acid derivative.
18. The method according to claim 1, wherein the serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is obtained from blood to which a blood coagulant has been added after collection from a living body.
19. The method according to claim 1, wherein the cell-free plasma or serum enriched in VEGF or IGF1 is a lyophilized product.
20. Cell-free plasma or serum produced by the method according to any one of claims 1 to 19.
21. A method for producing a plasma or serum processed product for producing cell-free plasma or serum enriched with VEGF or IGF1, the method comprising a step of subjecting the plasma or serum to ultrasonic disruption at an output of 5 W to 500 W to obtain a plasma or serum processed product.
Citation Information
Patent Citations
Enrichment method of platelet cell factor concentrates
CN107446036A
Preparation method of poultry plasma protein
CN108813090A
Preparation method of blood wall-breaking growth factor and application thereof
CN110028571A
Serum preparation apparatus
JP2013209409A
Method for producing platelet concentrated pharmaceutical preparation
JP2017171597A
